(CHD) Church & Dwight - Overview
Stock: Household Cleaners, Personal Care, Pet Supplies, Animal Feed
| Risk 5d forecast | |
|---|---|
| Volatility | 20.6% |
| Relative Tail Risk | 0.64% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.53 |
| Alpha | -13.25 |
| Character TTM | |
|---|---|
| Beta | -0.092 |
| Beta Downside | -0.393 |
| Drawdowns 3y | |
|---|---|
| Max DD | 27.28% |
| CAGR/Max DD | 0.23 |
EPS (Earnings per Share)
Revenue
Description: CHD Church & Dwight March 04, 2026
Church & Dwight Co., Inc. (CHD) develops, manufactures, and markets a range of consumer and specialty products. The company operates in three segments: Consumer Domestic, Consumer International, and Specialty Products. This diversified approach is common among established consumer goods companies, allowing for market penetration across various geographies and product categories.
Its brand portfolio includes ARM & HAMMER (baking soda, cat litter), OXICLEAN (stain removers), BATISTE (dry shampoos), WATERPIK (water flossers), THERABREATH (oral care), HERO (acne treatment), TOUCHLAND (hand sanitizers), and TROJAN (condoms). Other notable brands are FIRST RESPONSE (pregnancy tests), NAIR (depilatories), ORAJEL (oral analgesics), XTRA (laundry detergents), and ZICAM (cold relief). These brands span household, personal care, and health & wellness categories, demonstrating a broad market reach within the consumer staples sector.
The Specialty Products division focuses on animal and food productivity, offering products like ARM & HAMMER baking soda as a feed additive for dairy cows, BIO-CHLOR, FERMENTEN, CELMANAX, and CERTILLUS for livestock. These products are sold to industrial customers and livestock producers through distributors. Consumer products are distributed through various retail channels, including supermarkets, mass merchandisers, drugstores, and e-commerce platforms.
For more detailed financial analysis, consider exploring Church & Dwights performance data on ValueRay.
Headlines to watch out for
- Household product demand drives domestic revenue
- International expansion boosts sales growth
- Raw material costs impact profit margins
- Acquisition strategy fuels brand portfolio expansion
- Consumer spending trends influence product sales
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income: 736.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 1.27 > 1.0 |
| NWC/Revenue: 1.60% < 20% (prev 15.14%; Δ -13.54% < -1%) |
| CFO/TA 0.14 > 3% & CFO 1.22b > Net Income 736.8m |
| Net Debt (1.80b) to EBITDA (1.30b): 1.38 < 3 |
| Current Ratio: 1.07 > 1.5 & < 3 |
| Outstanding Shares: last quarter (239.6m) vs 12m ago -3.19% < -2% |
| Gross Margin: 44.73% > 18% (prev 0.46%; Δ 4.43k% > 0.5%) |
| Asset Turnover: 69.72% > 50% (prev 68.75%; Δ 0.97% > 0%) |
| Interest Coverage Ratio: 11.05 > 6 (EBITDA TTM 1.30b / Interest Expense TTM 95.2m) |
Altman Z'' 4.85
| A: 0.01 (Total Current Assets 1.60b - Total Current Liabilities 1.50b) / Total Assets 8.91b |
| B: 0.76 (Retained Earnings 6.77b / Total Assets 8.91b) |
| C: 0.12 (EBIT TTM 1.05b / Avg Total Assets 8.90b) |
| D: 1.43 (Book Value of Equity 7.04b / Total Liabilities 4.91b) |
| Altman-Z'' Score: 4.85 = AA |
Beneish M -2.99
| DSRI: 0.97 (Receivables 593.4m/600.8m, Revenue 6.20b/6.11b) |
| GMI: 1.02 (GM 44.73% / 45.69%) |
| AQI: 1.13 (AQ_t 0.73 / AQ_t-1 0.64) |
| SGI: 1.02 (Revenue 6.20b / 6.11b) |
| TATA: -0.05 (NI 736.8m - CFO 1.22b) / TA 8.91b) |
| Beneish M-Score: -2.99 (Cap -4..+1) = A |
What is the price of CHD shares?
Over the past week, the price has changed by -2.93%, over one month by -3.65%, over three months by +15.34% and over the past year by -9.78%.
Is CHD a buy, sell or hold?
- StrongBuy: 7
- Buy: 2
- Hold: 10
- Sell: 4
- StrongSell: 1
What are the forecasts/targets for the CHD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 103.6 | 3.9% |
| Analysts Target Price | 103.6 | 3.9% |
CHD Fundamental Data Overview March 11, 2026
P/E Forward = 26.5252
P/S = 3.9582
P/B = 5.9555
P/EG = 2.3062
Revenue TTM = 6.20b USD
EBIT TTM = 1.05b USD
EBITDA TTM = 1.30b USD
Long Term Debt = 2.21b USD (from longTermDebt, last quarter)
Short Term Debt = 28.9m USD (from shortTermDebt, two quarters ago)
Debt = 2.21b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.80b USD (from netDebt column, last quarter)
Enterprise Value = 26.35b USD (24.55b + Debt 2.21b - CCE 409.0m)
Interest Coverage Ratio = 11.05 (Ebit TTM 1.05b / Interest Expense TTM 95.2m)
EV/FCF = 24.11x (Enterprise Value 26.35b / FCF TTM 1.09b)
FCF Yield = 4.15% (FCF TTM 1.09b / Enterprise Value 26.35b)
FCF Margin = 17.62% (FCF TTM 1.09b / Revenue TTM 6.20b)
Net Margin = 11.88% (Net Income TTM 736.8m / Revenue TTM 6.20b)
Gross Margin = 44.73% ((Revenue TTM 6.20b - Cost of Revenue TTM 3.43b) / Revenue TTM)
Gross Margin QoQ = 45.85% (prev 45.06%)
Tobins Q-Ratio = 2.96 (Enterprise Value 26.35b / Total Assets 8.91b)
Interest Expense / Debt = 1.12% (Interest Expense 24.6m / Debt 2.21b)
Taxrate = 23.71% (44.6m / 188.1m)
NOPAT = 802.6m (EBIT 1.05b * (1 - 23.71%))
Current Ratio = 1.07 (Total Current Assets 1.60b / Total Current Liabilities 1.50b)
Debt / Equity = 0.55 (Debt 2.21b / totalStockholderEquity, last quarter 4.00b)
Debt / EBITDA = 1.38 (Net Debt 1.80b / EBITDA 1.30b)
Debt / FCF = 1.64 (Net Debt 1.80b / FCF TTM 1.09b)
Total Stockholder Equity = 4.29b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.28% (Net Income 736.8m / Total Assets 8.91b)
RoE = 17.16% (Net Income TTM 736.8m / Total Stockholder Equity 4.29b)
RoCE = 16.19% (EBIT 1.05b / Capital Employed (Equity 4.29b + L.T.Debt 2.21b))
RoIC = 12.35% (NOPAT 802.6m / Invested Capital 6.50b)
WACC = 5.19% (E(24.55b)/V(26.76b) * Re(5.58%) + D(2.21b)/V(26.76b) * Rd(1.12%) * (1-Tc(0.24)))
Discount Rate = 5.58% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -1.51%
[DCF] Terminal Value 87.34% ; FCFF base≈1.05b ; Y1≈1.16b ; Y5≈1.53b
[DCF] Fair Price = 182.9 (EV 45.08b - Net Debt 1.80b = Equity 43.28b / Shares 236.7m; r=5.90% [WACC]; 5y FCF grow 13.10% → 2.90% )
EPS Correlation: 37.07 | EPS CAGR: 0.95% | SUE: 0.66 | # QB: 0
Revenue Correlation: 89.06 | Revenue CAGR: 6.53% | SUE: 0.30 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.98 | Chg7d=+0.000 | Chg30d=+0.001 | Revisions Net=-10 | Analysts=17
EPS current Year (2026-12-31): EPS=3.77 | Chg7d=+0.000 | Chg30d=-0.005 | Revisions Net=+13 | Growth EPS=+6.8% | Growth Revenue=-0.3%
EPS next Year (2027-12-31): EPS=4.04 | Chg7d=+0.000 | Chg30d=+0.013 | Revisions Net=+7 | Growth EPS=+7.2% | Growth Revenue=+3.6%
[Analyst] Revisions Ratio: -0.83 (1 Up / 11 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.0% (Discount Rate 7.9% - Earnings Yield 3.0%)
[Growth] Growth Spread = -4.7% (Analyst 0.3% - Implied 5.0%)